|
1) Graus F, Delattre JY, Antoine JC, et al. Re-commended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004; 75: 1135-40
|
|
|
|
2) Titulae MJ, Soffietti R, Dalmau J, et al. Screening for tumors in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol. 2011; 18: 19-27
|
|
|
|
|
|
3) Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004; 127: 700-12
|
|
|
|
|
|
4) Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol. 2001; 50: 73-8
|
|
|
|
|
|
5) Lai M, Hujibers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010; 9: 776-85
|
|
|
|
|
|
6) Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leuchine-rich, glioma inactivated 1 protein and contactin associated protein-2 in limbic en-cephalitis, Morvanʼs syndrome and acquired neuro-myotonia. Brain. 2010; 133: 2734-48
|
|
|
|
|
|
7) Vincent A, Bien CG, Irani SR, et al. Auto-antibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011; 10: 759-72
|
|
|
|
|
|
8) Lancaster E, Huijbers MGM, Bar V, et al. Investigations of Caspar2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011; 69: 303-11
|
|
|
|
|
|
9) Jakob S, Irani SR, Rajabally YA, et al. Hypo-thermia in VGKC antibody-associated limbic en-cephalitis. J Neurol Neurosurg Psychiatry. 2008; 79: 202-4
|
|
|
|
|
|
10) Jarius S, Hoffmann L, Clover L, et al. CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. J Neurol Sci. 2008; 268: 74-7
|
|
|
|
|
|
11) Dalmau J, Tuzun E, Wu HY, et al. Pranaeoplastic anti-N-methyl D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007; 61: 25-36
|
|
|
|
|
|
12) Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008; 7: 1091-8
|
|
|
|
|
|
13) Dalmau J, Lancaster E, Martinez-Hermandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011; 10: 63-74
|
|
|
|
|
|
14) Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizure: case series and characterisation of the antigen. Lancet Neurol. 2010; 9: 67-76
|
|
|
|
|
|
15) Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009; 65: 424-34
|
|
|
|
|
|
16) 林 祐一, 松山善次郎, 高橋幸利, 他. 抗グルタミン受容体δ2, ε2抗体を認めた非ヘルペス性脳炎の1例. 臨床神経学. 2005; 45: 657-62
|
|
|
|
|
17) Ishiura H, Matsuda S, Higashihara M, et al. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology. 2008; 71: 1921-3
|
|
|
|
|